Blood Podcast

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Joshua Hill and Jeffery Weitz on their latest articles published in Blood. Dr. Hill and Dr. Michaelis discuss the evolving landscape of infection risk in adults receiving bispecific antibody therapies for advanced B‑cell malignancies. They explore how these risks differ from those seen with allogeneic transplant, CAR T‑cell therapy, and traditional CD20‑directed antibodies, and touch on emerging approaches such as trispecific antibodies and evolving strategies for supportive care, including immunoglobulin replacement. In the second half of the episode, Dr. Michaelis is joined by Dr. Jeffrey Weitz to discuss new insights into the role of histidine‑rich glycoprotein in hemostasis. Their conversation delves into HRG’s interactions with key platelet receptors, its behavior in inflammatory states like sepsis and COVID‑19, and how these observations may reshape thinking about thrombosis risk and future therapeutic approaches.Featured Articles: How I prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignancies | Joshua Hill, MDHistidine-rich glycoprotein modulates platelet adhesion and aggregation by binding to GPIbα and GPIIb/IIIa | Jeffery Weitz, MD

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Matthew Frank and Jieqing Zhu on their latest articles published in volume 147 issue 22 of Blood. Dr. Frank discusses "How I treat HLH-like toxicities after immune effector cell therapy", in which the two cases presented emphasize the need for early identification, the use of anticytokine therapy with either emapalumab or ruxolitinib when organ toxicities worsen despite conventional CRS-directed treatment, and the need for ancillary supportive care as central to success. Dr. Zhu shares insights from "Structural Basis of HPA-1 a Alloimmunization in FNAIT and Allosteric Regulation of Integrin Conformation" where they probed the structure-function relationships underpinning interactions of alloantibodies against the most common target, human platelet antigen 1a (HPA-1a). Their data can help explain why some alloantibodies cause severe hemorrhagic FNAIT while others result in milder, asymptomatic thrombocytopenia.

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Hanny Al-Samkari and Xin Zhou on their latest articles published in Blood. This episode highlights two important advances in hematology: the first report from the CHORUS registry for hereditary hemorrhagic telangiectasia (HHT) presented by Dr. Al-Samkari and also the introduction of the ASH Hematomics (ASHOP) platform for integrative genomic data analysis presented by Dr. Zhou. The CHORUS registry reveals that HHT is a progressive, underrecognized inherited bleeding disorder with a substantial burden of recurrent bleeding, iron deficiency, arteriovenous malformations, and life-threatening complications, while emphasizing the need for earlier diagnosis and the development of targeted therapies. The second presentation introduces ASHOP, an open-access platform that enables researchers to explore and integrate large-scale clinical and genomic datasets, facilitating discoveries in leukemia and other hematologic diseases through advanced analytical tools. Together, these studies demonstrate how comprehensive patient registries and innovative data-sharing resources are advancing precision medicine, improving disease understanding, and accelerating future research across hematology.